Verastem Inc (VSTM) Short Interest Update

Verastem Inc (NASDAQ:VSTM) was the recipient of a significant increase in short interest during the month of January. As of January 12th, there was short interest totalling 1,730,958 shares, an increase of 72.0% from the December 29th total of 1,006,283 shares. Based on an average daily trading volume, of 897,858 shares, the days-to-cover ratio is currently 1.9 days. Approximately 4.0% of the company’s shares are sold short.

A number of research analysts have recently commented on the company. Cann reaffirmed a “buy” rating and set a $6.00 target price on shares of Verastem in a research note on Tuesday, November 7th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Verastem in a research note on Wednesday, November 8th. Roth Capital assumed coverage on Verastem in a research note on Friday, December 1st. They set a “buy” rating and a $12.00 target price on the stock. Raymond James Financial reaffirmed a “buy” rating on shares of Verastem in a research note on Monday, December 11th. Finally, Oppenheimer set a $13.00 target price on Verastem and gave the company a “buy” rating in a research note on Thursday, December 21st. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $9.53.

In other Verastem news, Director Timothy J. Barberich bought 60,538 shares of the business’s stock in a transaction dated Tuesday, December 5th. The shares were purchased at an average price of $3.95 per share, with a total value of $239,125.10. Following the completion of the purchase, the director now owns 130,000 shares in the company, valued at approximately $513,500. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.51% of the company’s stock.

A number of large investors have recently made changes to their positions in VSTM. Point72 Asset Management L.P. bought a new position in Verastem in the third quarter worth approximately $6,580,000. EAM Investors LLC bought a new position in Verastem in the third quarter worth approximately $2,092,000. Dimensional Fund Advisors LP grew its stake in Verastem by 93.9% in the third quarter. Dimensional Fund Advisors LP now owns 561,969 shares of the biopharmaceutical company’s stock worth $2,641,000 after purchasing an additional 272,141 shares in the last quarter. Artal Group S.A. grew its stake in Verastem by 50.0% in the third quarter. Artal Group S.A. now owns 750,000 shares of the biopharmaceutical company’s stock worth $3,525,000 after purchasing an additional 250,000 shares in the last quarter. Finally, OxFORD Asset Management LLP bought a new position in Verastem in the second quarter worth approximately $234,000. 28.65% of the stock is currently owned by institutional investors.

Verastem (NASDAQ:VSTM) opened at $3.40 on Friday. Verastem has a 52 week low of $1.11 and a 52 week high of $5.71. The stock has a market capitalization of $153.89, a P/E ratio of -2.07 and a beta of 2.19. The company has a quick ratio of 3.12, a current ratio of 3.12 and a debt-to-equity ratio of 0.06.

Verastem (NASDAQ:VSTM) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.29). analysts expect that Verastem will post -1.74 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Verastem Inc (VSTM) Short Interest Update” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/28/verastem-inc-vstm-short-interest-update.html.

About Verastem

Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.

Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply